Vaccine Adjuvants Market Revenue to Attain USD 2.13 Bn by 2033

16 Dec 2024

Share :

Table of Content

1. Vaccine Adjuvants Market Revenue and Trends 2023 to 2033 2. Market Overview 3. Report Highlights of the Vaccine Adjuvants Market 4. Vaccine Adjuvants Market Trends 5. Regional Analysis 6. Vaccine Adjuvants Market Coverage 7. Vaccine Adjuvants Market Key Players 8. Market News

Vaccine Adjuvants Market Revenue and Trends 2023 to 2033

The global vaccine adjuvants market revenue reached USD 1.73 billion in 2024 and is predicted to attain around USD 2.13 billion by 2033 with a CAGR of 2.33%. The increasing demand to develop safe and effective vaccines is raising the adoption of the vaccine adjuvants market.

Market Overview

Vaccine adjuvants are composed as a part of a vaccine which is known to boost immune response and enhance the effectiveness of vaccines. Researchers and inventors can use adjuvants to improve the efficacy of actively used vaccines and to help develop new or improved vaccines for the treatment of infectious diseases. Another utilization of adjuvant vaccines is to treat allergies, autoimmune diseases, and cancer. Some populations such as compromised immune systems, pregnant people, older adults, and young people may benefit from adjuvanted vaccines.

Report Highlights of the Vaccine Adjuvants Market

• By type, the particulate segment captured the biggest share of the market in 2023. The dominance of this segment is due to the immune system stimulation it creates to induce inflammatory responses.
• By type, the pathogen segment shows notable growth during the forecast period. The expansion of this segment is experienced owing to the stimulating innate immune response.
• By administration, the intramuscular segment contributed the highest share in the market in 2023. The intramuscular route of administration is gaining traction due to its ability for rapid absorption than subcutaneous injection.
• By administration, the intradermal segment will show notable growth in the market during the forecast period. The growth of the intradermal route of administration is noticed as it has the longest absorption time of all parenteral routes.
• By application, the infectious disease segment contributed the highest share in the market in 2023. The dominance of this segment is observed as it improves the vaccine efficiency by enhancing the immune response to a vaccine’s antigens.
• By application, the cancer segment is anticipated to grow at the fastest CAGR in the market during the forecast period. The expansion of this segment can be credited to the utilization of adjuvants in preventative vaccines and therapeutic vaccines to enhance immune response but also uses personalized tumor antigens.

Vaccine Adjuvants Market Trends

• Rising global health challenges: The increasing number of infectious diseases and the emergence of new pathogen are induing a significant healthcare challenge worldwide. This leads to propelling the demand for the vaccine adjuvants market which will help reduce the risks of getting the disease by building a better immune system and natural defence to protect.
• Broadening immunization initiatives: Several initiatives emphasize the development and expansion of immunization programs worldwide. These resourcefulness aims to make immunization against diphtheria, poliomyelitis, pertussis, tetanus, measles, and tuberculosis which are observed in every child globally. The Expanded Programme on Immunization (EPI) helps to standardize immunization schedules, improve vaccine availability, promote safe injection technology, and protect vaccine potency through cold chain management.

Regional Analysis

North America dominated the global vaccine adjuvants market in 2023. The region’s dominance is attributed to the government and organization initiatives in the development of vaccines. The U.S. has been a courageous and innovative leader in the global fight against COVID-19. The U.S. offered great support and expanded its leadership by launching initiatives for global vaccine access. Through this, the U.S. government increased its decades of investments in global health and diplomatic partnership to provide help to 120 countries fighting COVID-19. All vaccines must be approved and licensed by the Food and Drug Administration (FDA), followed by the vaccine evaluation through experts who make trial data and recommend the vaccine for use.

Middle East and Africa are anticipated to register significant growth in the vaccine adjuvants market during the forecast period. The lack of protection for preventable disease is contributing to the growth of this region which is noticed due to the steady decline in vaccination coverage. With the help of enhancing evidence-based exchange and increasing the awareness of the safety and benefits of the seasonal vaccination.

Vaccine Adjuvants Market Coverage

Vaccine Adjuvants Market Key Players

• GlaxoSmithKline plc
• Agenus
• Merck KGaA
• InvivoGen
• CSL Limited
• Dynavax Technologies
• Croda International PLC
• OZ Biosciences
• SEPPIC
• SPI Pharma
• Phibro Animal Health Corporation
• Sanofi
• Aphios Corporation
• Avanti Polar Lipids, Inc.
• Vertellus

Market News

• In May 2024, Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, entered into a co-exclusive licensing agreement with Sanofi. Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate.
• In October 2024, AdJane, a company specializing in the development of vaccine adjuvants aimed at enhancing vaccine efficacy, launched as a pioneer in the field of vaccine adjuvants, dedicated to enhancing the efficacy of vaccines. With a commitment to innovation and excellence.

Market Segmentation

By Type

• Pathogen
• Adjuvant Emulsion
• Particulate
• Combination
• Others

By Application

• Infectious Disease
• Cancer 
• Others

By Administrator

• Oral 
• Intradermal
• Intranasal
• Intramuscular
• Others

Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/5349

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344